Introduction {#Sec1}
============

GATA binding protein 2 (GATA2) belongs to the GATA family of transcription factors which regulate hematopoietic stem cell proliferation and differentiation^[@CR1],[@CR2]^. *GATA2* mutations have been reported in acute myeloid transformation of chronic myeloid leukemia (CML)^[@CR3]^, familial myelodysplastic syndrome-related acute myeloid leukemia (MDS/AML), pediatric MDS^[@CR4],[@CR5]^, Emberger syndrome^[@CR6]^, and monocytopenia and mycobacterial infection (MonoMAC) syndrome^[@CR7],[@CR8]^. Mutations of *GATA2* are also identified in AML patients, with an incidence varied from 3.6% in patients with French-American-British (FAB) M5 subtype^[@CR4]^ to 8.1--14.4% in non-selected AML patients^[@CR9]--[@CR11]^.

Somatic *GATA2* mutations mainly cluster in the two zinc finger (ZF) domains, which can occupy GATA DNA motif in thousands of genes^[@CR9]^. The patterns of somatic *GATA2* mutations differ among myeloid diseases. ZF1 mutations predominate in AML, and ZF2 mutations are frequently identified in CML blastic phase^[@CR3]^. *GATA2* mutations are strongly associated with *CEBPA* double mutations (*CEBPA*^double-mut^)^[@CR9],[@CR10],[@CR12]^. However, discrepancies exist among different reports regarding prognostic impact of *GATA2* mutations in AML patients^[@CR10],[@CR13]^. We hypothesize that mutations in different domains of *GATA2* may have distinct impact on clinico-biological features and outcomes in AML patients, like *IDH2* mutations in which *IDH2* R172 is associated with gene mutations and clinical outcomes different from other *IDH* mutations^[@CR14]^. However, little is known about this issue till now.

In this study, we investigated the clinical and prognostic relevance of mutations in different *GATA2* domains in a large cohort of 693 unselected *de novo* non-M3 AML patients. To our knowledge, this is the first study to show *GATA2* ZF1 mutations are associated with distinct clinical features, gene mutations, and outcomes different from ZF2 mutations. Longitudinal follow-ups were also performed in 419 samples from 124 patients to evaluate the dynamic changes of the mutations. Furthermore, we analyzed the global gene expression profiles in 328 patients to interrogate the possible molecular pathways associated with mutations in different *GATA2* domains.

Methods and materials {#Sec2}
=====================

Subjects {#Sec3}
--------

We consecutively enrolled 693 newly diagnosed *de novo* non-M3 AML patients at the National Taiwan University Hospital (NTUH) from 1994 to 2011. Diagnosis and classification of AML were made according to the FAB Cooperative Group Criteria and the 2016 WHO classification^[@CR15]^. To focus on a more homogeneous group of patients with *de novo* AML, those with antecedent hematological diseases, history of cytopenia, and family history of myeloid neoplasms or therapy-related AML were excluded^[@CR16]^. Survival analyses were performed in 469 (67.7%) patients who received standard chemotherapy. This study was approved by the Institutional Review Board of the NTUH, and written informed consents were obtained from all participants in accordance with the Declaration of Helsinki.

Cytogenetics {#Sec4}
------------

Chromosomal analyses were performed as described previously^[@CR17]^. Karyotypes were classified using Medical Research Council (MRC) risk groups^[@CR18]^.

Mutation analysis {#Sec5}
-----------------

Mutation analysis of *GATA2* exons 2--6^[@CR12]^ and 20 other genes, including *FLT3*-ITD^[@CR19]^, *FLT3*-TKD^[@CR19]^, *NRAS*^[@CR19]^, *KRAS*^[@CR19]^, *KIT*^[@CR19]^, *PTPN11*^[@CR20]^*, CEBPA*^[@CR21]^, *RUNX1*^[@CR22]^, *MLL*-PTD^[@CR23]^, *ASXL1*^[@CR24]^, *IDH1*^[@CR25]^, *IDH2*^[@CR25]^, *TET2*^[@CR26]^, *DNMT3A*^[@CR16]^, *SF3B1*^[@CR27]^, *SRSF2*^[@CR27]^, *U2AF1*^[@CR27]^, *NPM1*^[@CR28]^, *WT1*^[@CR29]^, *TP53*^[@CR30]^, and *ETV6*^[@CR31]^ were performed by Sanger sequencing as previously described for patients (*n* = 455) diagnosed from 1994 to 2007. For patients (*n* = 238) diagnosed after 2008, Ion torrent next-generation sequencing (NGS) (Thermo Fisher Scientific, MA, USA) was performed^[@CR32]^. Serial analyses of mutations at diagnosis, complete remission (CR), and relapse were performed in 419 samples from 124 patients by targeted NGS using TruSight Myeloid Panel (Illumina, San Diego, CA, USA). HiSeq platform (Illumina) was used for sequencing with a median reading depth of 12,000× ^[@CR32]^.

Functional annotation analysis of *GATA2* mutation-regulated genes {#Sec6}
------------------------------------------------------------------

We analyzed the differentially expression genes associated with *GATA2* mutations by the knowledge-based Ingenuity Pathway Analysis (IPA) (Qiagen, Redwood City, CA) software for associated functions. We also used Gene Set Enrichment Analysis (GSEA) software to investigate systematic enrichments of *GATA2* mutation-governed expressional profile in biological functions^[@CR33]^. Statistical significance of the degree of enrichment was assessed by a 1000-time random permutation test.

Statistical analysis {#Sec7}
--------------------

The discrete variables were compared using the *χ*^2^ tests, but if the expected values of contingency tables were \<5, Fisher's exact test was used. Mann--Whitney *U* tests were used to compare continuous variables and medians of distributions. Overall survival (OS) was measured from the date of first diagnosis to the date of last follow-up or death from any cause. Disease-free survival (DFS) was measured from the date of diagnosis until treatment failure, relapse from CR, or death from any cause, whichever occurred first. To ameliorate the influence of hematopoietic stem cell transplantation (HSCT) on survival, DFS and OS were censored at the time of HSCT in patients receiving the treatment^[@CR34]^. Multivariate Cox proportional hazard regression analysis was used to investigate independent prognostic factors for OS and DFS. A *P* value \<0.05 was considered statistically significant. All statistical analyses were performed with the SPSS 18 (SPSS Inc., Chicago, IL, USA) and StatsDirect (Cheshire, England, UK).

Results {#Sec8}
=======

*GATA2* mutations in patients with AML {#Sec9}
--------------------------------------

Excluding two single-nucleotide polymorphisms (A164T, M400T)^[@CR35]^ and eight missense mutations (N114T, M223I, P250A, A256V, L315P, C319F, V369A, S429T) with unknown biologic significance (because they were not reported previously and could not be verified because of lack of matched bone marrow samples in CR), we identified 44 distinct *GATA2* mutations in 43 (6.2%) of 693 patients (Fig. [1](#Fig1){ref-type="fig"}). Forty *GATA2* mutations were missense mutations. The other four were in-frame deletion or duplication: p.Ser201\*(c.598_599insG) in two, p.Thr387_Gly392del (c.1160_1177delCCATGAAGAAGGAAGGGA) and G210dup (c.631_632insGCG) in one each. With regard to the functional sites, 31 mutations were clustered in the highly conserved N-terminal ZF domain (ZF1 domain), and other 10 mutations were within C-terminal ZF domain (ZF2 domain). The remaining three mutations scattered outside of the ZF domains. The most common mutations were A318V (*n* = 4), followed by L321F and A318T (*n* = 3 each). p.Ser201\*(c.598_599insG), N297S, A318G, G320V, L321H, and K324E occurred in two patients each. All other mutations were detected in only one patient each (Table [1](#Tab1){ref-type="table"}). Only one patient had two *GATA2* mutations (patient no. 20). All mutations were heterozygous. The mutant burden ranged from 4.89 to 52% with a median of 39.07% in ZF1 mutations, and from 10.74 to 50.26% with a median of 36.16% in ZF2 mutations.Fig. 1Patterns and locations of the 44 *GATA2* mutationsTable 1The mutation patterns in 43 patients with *GATA2* mutations at diagnosis*GATA2* mutationsUPNAge/sexKaryotypeLocationDNA changeMutant burden (%)Protein changeOther mutations129FCNZF1c.953C\>T52A318V*CEBPA*^dm^, *FLT3*-ITD, *NRAS*240MCNZF1c.961C\>T49.37L321F*CEBPA*^dm^, *NRAS*365Ft(3;3)(q21;q26),del(12)(p11p13)ZF1c.890A\>G49.04N297S*NRAS*, *ASXL1*436MCNZF1c.961C\>T47.42L321F*CEBPA* ^dm^537M−YZF1c.959G\>T47.19G320V*CEBPA* ^dm^636MCNZF1c.970A\>G46.14K324E*CEBPA*^dm^, *NRAS*727MCNZF1c.953C\>G45.45A318G*CEBPA* ^dm^878F+8ZF1c.1009C\>T45.3R337X*FLT3*-ITD, *NRAS*, *IDH2*, *SRSF2*942Mt(3;3)(q21;q26)/46,idem,add(17)(p13)ZF1c.959G\>A44.62G320D*ASXL1*, *U2AF1*1034MCNZF1c.962T\>A43.97L321H*CEBPA*^sm^, *NRAS*, *KIT*, *IDH2*, *DNMT3A*1120FCNZF1c.989G\>A43.14R330Q*CEBPA*^dm^, *ASXL1*1232MCNZF1c.952G\>A42.99A318T*CEBPA*^dm^, *KIT*1339MCNZF1c.911C\>T42.41P304L*MLL*, *TET2*1443MCNZF1c.923G\>C41.21R308P*CEBPA*^dm^, *NRAS*1518Mdel(9)(q22q34)ZF1c.926A\>G39.07D309V*CEBPA* ^sm^1636FCNZF1c.920G\>A39.06R307Q*CEBPA*^dm^, *NRAS*1731FCNZF1c.970A\>G37.98K324E*CEBPA* ^dm^1855MCNZF1c.952G\>A32.72A318T*CEBPA* ^dm^1969FCNZF1c.953C\>T30.26A318V*CEBPA* ^dm^2057MCNZF1c.962T\>A c.949A\>C23.94L321H, N317H*CEBPA*^dm^, *TET2*2151M+21ZF1c.953C\>T23.48A318V*CEBPA*^dm^, *RUNX1*2239F46,XX,der(3)t(3;17)(q26;q21),t(16;17)(p11;q11)ZF1c.962T\>C20.48L321P*SF3B1*2382MCNZF1c.951T\>A20.46N317K*RUNX1*, *SF3B1*2419FCNZF1c.959G\>C18.41G320A*CEBPA*^dm^, *FLT3-*TKD2559MCNZF1c.953C\>T18.15A318V*CEBPA*^dm^, *NRAS*2629MCNZF1c.961C\>T17.58L321F*CEBPA* ^sm^2750MCNZF1c.959G\>T13.81G320V*CEBPA*^dm^, *U2AF1*2854MCNZF1c.953C\>G10.81A318G*CEBPA* ^dm^2922Fdel(9q)ZF1c.952G\>A6.02A318T*CEBPA* ^dm^3078MCNZF1c.890A\>G4.89N297S*PTPN11*, *DNMT3A*3176MCNZF2c.1075T\>G50.26L359V*RUNX1*3253FCNZF2c.1085G\>A48.68R362Q*ASXL1*, *IDH2*, *DNMT3A*3328FCNZF2c.1114G\>A46.82A372T*NPM1*3469FCNZF2c.1096G\>A46.33G366R*NPM1*3518FCNZF2c.1114G\>A39.8A372T*NPM1*, *PTPN11*3620MCNZF2c.1084C\>G23.05R362G*CEBPA*^sm^, *ASXL1*3740Ft(7;11)ZF2c.1114G\>A21.36A372T*FLT3-*ITD, *NRAS*3860M−YZF2c.1084C\>G32.52R362G*-*3932F+10ZF2c.1160_1177delCCATGAAGAAGGAAGGGA17.59Thr387_Gly392del*CEBPA*^dm^, *NRAS*4080FCNZF2c.1061C\>T10.74T354M*CEBPA*^dm^, *FLT3*-ITD4171Mdel(12)(p12p13), −7c.598_599insG35.31Ser201*PTPN11*, *RUNX1*, *ASXL1*4268FCNc.598_599insG34.1Ser201*FLT3-*ITD, *RUNX1*, *MLL*4376MCNc.631_632insGCG40.36G210dup*TP53UPN* unique patient number, *CEBPA*^dm^ *CEBPA* double mutation, *CN* cytogenetically normal, *ZF* zinc finger

Correlation of *GATA2* mutations with clinical and laboratory features {#Sec10}
----------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} depicted the clinical characteristics of patients with and without *GATA2* mutations. ZF1-mutated patients were younger (median, 39 years vs. 55 years, *P* = 0.004), and had higher incidence of FAB M1 subtype (56.7% vs. 22.1%, *P* \< 0.0001), but lower incidence of FAB M4 subtype (3.3% vs. 28.1%, *P* = 0.003) than *GATA2-*wild patients. ZF1-mutated patients also had a higher incidence of FAB M1 subtype than ZF2-mutated patients (*P* = 0.044). The patients with ZF2 mutations showed similar clinical features to the *GATA2-*wild group, including peripheral white blood cell counts (median, 47.3 vs. 18.7 k/µL), incidences of FAB M1 subtype (20% vs. 22.1%), and M4 subtype (20% vs. 28.1%).Table 2Comparison of clinical and laboratory features between AML patients with *GATA2* ZF1 domain and ZF2 domain mutationsVariables*GATA2-*wild (*n* = 650)*GATA2* mutations (*n* = 43)*P* value^a^ZF1 domain mutations (*n* = 30)*P* value^b^ZF2 domain mutations (*n* = 10)*P* value^c^Sex^d^0.8760.2910.112Male370 (56.9)25 (58.1)20 (66.7)3 (30)Female280 (43.1)18 (41.9)10 (33.3)7 (70)Age (year)^e^55 (15--94)40 (18--82)0.01739 (18--82)0.00447 (18--80)0.365Lab data^e^WBC (k/μL)18.7 (0.12--423)21.2 (1.23--627.8)0.20023.4 (1.33--627.8)0.19547.3 (1.23--212.7)0.494Hb (g/dL)8.1 (2.9--16.2)8.1 (4.2--13.2)0.7048.1 (4.4--12.5)0.4367.4 (4.2--13.2)0.311Platelet (k/μL)47 (3--802)45 (6--1017)0.56547 (6--1017)0.93747 (11--119)0.606PB Blast(k/μL)7.33 (0--371.9)9.09 (0--456.7)0.07711.3 (0.06--456.7)0.06729.9 (0--140.7)0.358LDH (U/L)859 (206--15000)917 (299--4220)0.575970 (327--4220)0.3851029 (394--2970)0.629FAB^d^M016 (2.5)2 (4.7)0.3092 (6.7)0.1860 (0)\>0.999M1144 (22.1)21 (48.8)\<0.000117 (56.7)\<0.00012 (20)\>0.999M2239 (36.8)17 (39.5)0.71610 (33.3)0.7036 (60)0.186M4183 (28.1)3 (7.0)0.0021 (3.3)0.0032 (20)0.734M531 (4.8)0 (0)0.2480 (0)0.6330 (0)\>0.999M627 (4.2)0 (0)0.4030 (0)0.6250 (0)\>0.999Unclassified10 (1.5)0 (0)\>0.9990 (0)\>0.9990 (0)\>0.9992016 WHO classification^d^ t(8;21)57 (8.7)0 (0)0.0410 (0)0.1650 (0)\>0.999 Inv(16)27 (4.2)0 (0)0.4030 (0)0.6250 (0)\>0.999 t(9;11)9 (1.4)0 (0)\>0.9990 (0)\>0.9990 (0)\>0.999 t(6;9)3 (0.5)0 (0)\>0.9990 (0)\>0.9990 (0)\>0.999 Inv(3)1 (0.2)2 (4.6)0.0112 (6.7)0.0050 (0)\>0.999 t(1;22)0 (0)0 (0)--0 (0)--0 (0)--* CEBPA* ^dm^43 (6.6)22 (51.2)\<0.000120 (66.7)\<0.00012 (20)0.144* NPM1*139 (21.3)3 (7.0)0.0230 (0)0.0053 (30)0.455* RUNX1*73 (11.2)4 (9.3)\>0.9991 (3.3)0.2371 (10)\>0.999 BCR-ABL1 (0.2)0 (0)\>0.09990 (0)\>0.9990 (0)\>0.999 MRC93 (14.3)0 (0)0.0080 (0)0.0250 (0)0.372 AML, NOS204 (31.4)12 (27.9)0.6337 (23.3)0.3514 (40)0.516Induction response^f^43138279Complete remission323 (74.9)29 (76.3)0.85123 (85.2)0.2305 (60)0.241Induction death32 (7.4)1 (2.6)0.5030 (0)0.2431 (10)0.508Relapse161 (49.8)9 (31)0.0528 (34.8)0.1631 (16.7)0.371*CEBPA*^sm^ *CEBPA* single mutation, *CEBPA*^dm^ *CEBPA* double mutation, *MRC* myelodysplasia-related change, *NOS* not otherwise specified, *PB* peripheral blood^a^*GATA2*-mutated patients vs. *GATA2* wild-type patients^b^*GATA2* ZF1-mutated patients vs. *GATA2* wild-type patients^c^*GATA2* ZF2-mutated patients vs. *GATA2* wild-type patients^d^Number of patients (%)^e^Median (range)^f^Only the 469 patients, including 27 with *GATA2 ZF1* domain mutations, nine with *GATA2 ZF2* domain mutations, and 431 without, who received conventional intensive induction chemotherapy and then consolidation chemotherapy if CR was achieved, as mentioned in the text, were included in the analysis

Association of *GATA2* mutations with cytogenetics abnormalities {#Sec11}
----------------------------------------------------------------

Chromosome data were available in 669 patients at diagnosis, including 43 *GATA2*-mutated and 626 *GATA2*-wild patients (Supplementary Table [1](#MOESM1){ref-type="media"}). Totally, *GATA2* mutations were closely associated with intermediate-risk cytogenetics. Compared to *GATA2*-wild patients, ZF1-mutated patients had more intermediate-risk cytogenetics (100% vs. 70.9%, *P* \< 0.0001), normal karyotype (73.3% vs. 46.5%, *P* = 0.004), and t(3;3) (6.7% vs. 1.0%, *P* = 0.048), but less favorable-risk (0% vs. 13.6%, *P* = 0.024) or unfavorable-risk cytogenetics (0% vs. 15.5%, *P* = 0.014). There was no association of ZF1 mutations with other chromosomal abnormalities, including +8, +11, +13, and +21.

Association of *GATA2* mutations with other molecular alterations {#Sec12}
-----------------------------------------------------------------

To investigate the interaction of *GATA2* ZF1 and ZF2 mutations with other genetic alterations in the pathogenesis of adult AML, a complete mutational screening of 20 other genes was performed. Only ZF1-mutated patients had a significantly higher frequency of *CEBPA*^double-mut^ (66.7% vs. 6.7%, *P* \< 0.0001) than wild-type patients, but not ZF2-mutated patients (Table [3](#Tab3){ref-type="table"}). ZF1-mutated patients had lower frequencies of *NPM1* mutations (0% vs. 22%, *P* = 0.004) and *FLT3*-ITD (4% vs. 19.9%, *P* = 0.024) than wild-type patients. In contrast, ZF2-mutated patients had similar frequencies of *NPM1* mutations (30%) and *FLT3*-ITD (20%) to those with wild type of *GATA2*. Both ZF1 and ZF2 mutations were mutually exclusive with *KRAS*, *WT1*, *IDH1*, *TP53*, and *ETV6* mutations (Table [3](#Tab3){ref-type="table"}).Table 3Comparison of other genetic alterations between AML patients according to *GATA2* mutation domainMutationTotal pts examinedPts with the other gene mutations (%)*P* value^a^*P* value^b^*P* value^c^Whole cohort*GATA2* wt pts*GATA2* mutated ptsZF1ZF2*FLT3*-ITD68519.319.99.34.0200.0870.024\>0.999*FLT3-*TKD6908.89.22.43.300.2480.508\>0.999*NRAS*69115.514.826.830250.0380.0350.340*KRAS*6883.63.90000.3910.620\>0.999*PTPN11*65854.87.73.612.50.436\>0.9990.335*KIT*6904.84.84.96.70\>0.9990.652\>0.999*WT1*6886.87.30000.1030.257\>0.999*NPM1*69321.12270300.0190.0040.467*CEBPA*68914.211.160.576.730\<0.0001\<0.00010.095*CEBPA* ^*dm*^6899.46.751.266.720\<0.0001\<0.00010.146*RUNX1*6841414.211.96.711.10.6820.413\>0.999*MLL/*PTD6365.75.75.13.60\>0.999\>0.999\>0.999*ASXL1*69114141410200.9870.7860.640*IDH1*6906.46.80000.1010.250\>0.999*IDH2*69112.713.17.16.711.10.2620.410\>0.999*TET2*67011.912.44.96.900.2120.5620.610*DNMT3A*68517.4187.36.911.10.0800.124\>0.999*TP53*6857.78.12.4000.2410.158\>0.999*ETV6*6490.90.9000\>0.999\>0.999\>0.999SF65311.811.712.517.900.8020.3660.608Pts patients, *CEBPA*^*dm*^ *CEBPA*^*double-mutation*^, *SF* splicing factors, including *SF3B1*, *SRSF2*, and *U2AF1*^a^*GATA2*-mutated patients vs. *GATA2* wild-type patients^b^*GATA2* ZF1-mutated patients vs. *GATA2* wild-type patients^c^*GATA2* ZF2-mutated patients vs. *GATA2* wild-type patients

Impact of different *GATA2* domains mutations on treatment response and clinical outcomes {#Sec13}
-----------------------------------------------------------------------------------------

Of the 469 AML patients, including 27 *GATA2* ZF1-mutated and nine *GATA2* ZF2-mutated patients, undergoing conventional intensive induction chemotherapy, 352 (75.1%) patients achieved a CR. The CR rate was 85.2% in ZF1-mutated patients and 60% in ZF2-mutated patients (Table [2](#Tab2){ref-type="table"}). The relapse rate was similar between the two groups.

With a median follow-up time of 78.6 months (ranges, 0.1--236 months), patients with *GATA2* mutations as a whole had a trend of longer OS (5-year survival rate, 56% vs. 43%, *P* = 0.078) and DFS (median, 32.9 vs. 8.8 months, *P* = 0.091) than those without *GATA2* mutations (Supplementary Figure [1](#MOESM1){ref-type="media"}). Focusing on the prognostic implication of mutation sites, patients with *GATA2* ZF1 mutations had a significantly better OS (5-year survival rate, 72% vs. 43%, *P* = 0.003) and DFS than *GATA2-*wild patients (median, 91.2 vs. 8.8 months, *P* = 0.022) (Fig. [2](#Fig2){ref-type="fig"}). In contrast, patients with *GATA2* ZF2 mutations had similar OS (5-year survival rate, 31%, *P* = 0.297) and DFS (median, 4.4 months, *P* = 0.882) as the *GATA2-*wild group. Intriguingly, ZF1 mutations were also associated with better OS compared with ZF2 mutations (*P* = 0.001) (Fig. [2](#Fig2){ref-type="fig"}). In intermediate-risk cytogenetics group, ZF1-mutated patients had significantly superior OS (5-year survival rate, 72% vs. 39%, *P* = 0.009) and DFS (median, 91.2 vs. 7.8 months, *P* = 0.006) than *GATA2-*wild patients, and a longer OS (5-year survival rate, 72% vs. 31%, *P* = 0.007) and a trend toward longer DFS (median, 91.2 vs. 4.4 months, *P* = 0.133) than ZF2-mutated patients (Fig. [3](#Fig3){ref-type="fig"}). The finding also held true in normal karyotype subgroup (Supplementary Figure [2](#MOESM1){ref-type="media"}). Multivariate analysis demonstrated that ZF1 mutation was an independent favorable prognostic factor for OS (HR 0.207, 95% CI 0.066--0.652, *P* = 0.007) and DFS (HR 0.529, 95% CI 0.295--0.948, *P* = 0.032) irrespective of age, white blood cell counts, cytogenetics, *NPM1*, and *FLT3-*ITD status. However, the prognostic independence of ZF1 mutation was lost if we included *CEBPA*^double-mut^ as a covariable (Supplementary Table [2](#MOESM1){ref-type="media"}). We could not find the survival difference stratified by the degree of mutational burden in either ZF1 or ZF2-mutated patients (data not shown). Allo-HSCT in CR1 for ZF1-mutated patients did not offer survival benefit compared to postremission chemotherapy alone (data not shown).Fig. 2**Kaplan--Meier survival curves for OS (a) and DFS (b) stratified by the** ***GATA2*** **mutation status and the sites of mutations in 467 AML patients who received standard intensive chemotherapy.** Patients with *GATA2* ZF1 mutations had a significantly better OS (5-year survival rate, 72% vs. 43%, *P* = 0.003) and DFS than *GATA2-*wild patients (median, 91.2 vs. 8.8 months, *P* = 0.022). Patients with *GATA2* ZF2 mutations had similar OS (5-year survival rate, 31%, *P* = 0.297) and DFS (median, 4.4 months, *P* = 0.882) as the wild-type group. ZF1 mutations were also associated with better OS compared with ZF2 mutations (*P* = 0.001)Fig. 3**Kaplan--Meier survival curves for OS (a) and DFS (b) stratified by the** ***GATA2*** **mutation status and the sites of mutations in 328 intermediate-risk cytogenetics patients who received standard intensive chemotherapy.** Patients with *GATA2* ZF1 mutations had a significantly better OS (5-year survival rate, 72% vs. 39%, *P* = 0.009) and DFS (median, 91.2 vs. 7.8 months, *P* = 0.006) than *GATA2-*wild patients. Patients with *GATA2* ZF2 mutations had similar OS and DFS as the wild-type group (*P* = 0.504, *P* = 0.989, respectively). ZF1 mutations were also associated with a longer OS (5-year survival rate, 72% vs. 31%, *P* = 0.007) and a trend toward longer DFS (median, 91.2 vs. 4.4 months, *P* = 0.133) compared with ZF2 mutations

In *CEBPA*^double-mut^ subgroup, *GATA2* ZF1*-*mutated patients had a trend of longer OS (5-year survival rate, 76% vs. 68%, *P* = 0.075) and a significantly longer DFS (median, 91.2 vs. 14.0 months, *P* = 0.034) than *GATA2*-wild patients (Fig. [4](#Fig4){ref-type="fig"}). ZF1 mutations allowed further refinement of the clinical outcome of *CEBPA*^double-mut^ patients. The small number of ZF2-mutated patients (*n* = 3) in this group did not allow statistically meaningful correlations.Fig. 4**Comparison of OS (a) and DFS (b) among** ***CEBPA***^double-mut^**/*GATA2*** **ZF1-mutated,** ***CEBPA***^double-mut^**/*GATA2-*wild and** ***CEBPA-*wild AML patients who received standard intensive chemotherapy**. C*EBPA*^double-mut^ patients with *GATA2* ZF1 mutations had a trend of longer OS (5-year survival rate, 76% vs. 68%, *P* = 0.075) and a significantly longer DFS (median, 91.2 vs. 14.0 months, *P* = 0.034) that those with wild-type *GATA2*. The small number of ZF2-mutated patients in C*EBPA*^double-mut^ patients did not allow statistically meaningful correlations

Sequential studies of *GATA2* mutations in AML patients {#Sec14}
-------------------------------------------------------

*GATA2* mutations were serially studied in 419 samples from 124 patients who had ever obtained a CR and had available samples for study, including 19 patients with and 105 patients without *GATA2* mutations at diagnosis (Table [4](#Tab4){ref-type="table"}). Among the 19 *GATA2*-mutated patients who had paired samples, all lost the original *GATA2* mutations at remission. Five of the six patients regained the original *GATA2* mutations at first relapse, but one (no. 27) lost the mutation. In the former five patients, the mutation burden, compared to that at diagnosis, was increased in one patient (no. 25), decreased in two (nos. 13 and 16), and stable in the remaining two (nos. 5 and 9). One patient (no. 9) retained the co-occurring *ASXL1* mutations at CR status. Among the 105 patients who had no *GATA2* mutations at diagnosis, four patients (nos. 44, 45, 46, and 47) acquired novel *GATA2* mutations at relapse (Table [4](#Tab4){ref-type="table"}).Table 4Sequential studies in the AML patients with *GATA2* mutations^a^UPNInterval^b^ (months)Status*GATA2* mutationsAllele burdenOther mutations1InitialAla318Val52*CEBPA*, *FLT3-ITD*, *NRAS*0.9CR1−0−4InitialLeu321Phe47.42*CEBPA*1.3CR1−0*−*5InitialGly320Val47.19*CEBPA*6.6CR1−0−27.1Relapse1Gly320Val43.1*CEBPA*1.0CR2−0−6InitialLys324Glu46.14*CEBPA*, *NRAS*0.9CR1−0*−*7InitialAla318Gly45.45*CEBPA*0.9CR1−0*−*9InitialGly320Asp44.62*ASXL1*, *U2AF1*3.2CR1−0*ASXL1*6.5Relapse1Gly320Asp43.2*ASXL1*12InitialAla318Thr42.99*CEBPA*, *KIT*0.9CR1−0*−*13InitialPro304Leu42.41*MLL*, *TET2*3.5CR1−0*−*6.3Relapse1Pro304Leu3.2*−*14InitialArg308Pro41.21*CEBPA*, *NRAS*1.4CR1−0*-*16InitialArg307Gln39.06*CEBPA*, *NRAS*3.0CR1−0*−*34.7Relapse1Arg307Gln27*CEBPA*18InitialAla318Thr32.72*CEBPA*2.1CR1−0*−*20InitialLeu321His, Asn317His11.3*CEBPA*, *TET2*23.941.4CR1−0, 0*−*21InitialAla318Val23.48*CEBPA*, *RUNX1*1.0CR1−0*−*24InitialGly320Ala18.41*CEBPA*, *FLT3*-TKD0.9CR1−0*−*25InitialAla318Val18.15*NRAS*, *CEBPA*1.2CR1−0−12.0Relapse1Ala318Val43.5*CEBPA*27InitialGly320Val13.81*CEBPA*, *U2AF1*1.0CR1−0−3.5Relapse1−0*CEBPA*11.7CR2−0−5.9Relapse2−0*CEBPA*29InitialAla318Thr6.02*CEBPA*1.0CR1−039InitialThr387_Gly392del17.59*CEBPA*, *NRAS*1.0CR1−0*−*41InitialSer20135.31*PTPN11*, *RUNX1*, *ASXL1*0.8CR1−0*−*44Initial−0*CEBPA*, *DNMT3A*4.5CR1−0*DNMT3A*2.9Relapse1Glu180LysfsTer387.1*DNMT3A*1.1CR2−0−6.0Relapse2−0*DNMT3A*2.0CR3−0−45Initial−0*DNMT3A*, *NPM1*, *NRAS*, *PTPN11*7.3CR1−0*DNMT3A*12.5Relapse1Arg307Leu5.6*DNMT3A*, *NPM1*1.2CR2−0*DNMT3A*13.6Relapse2−0*DNMT3A*, *NPM1*46Initial−0*CEBPA*2.9CR1−0−14.2Relapse1Leu321Pro26*CEBPA*4729.0Initial−0*−*1.0CR1−0−15.6Relapse1Gly320Asp15.9−Leu321His15.13.6CR2−0−11.8Relapse2Leu321His39.4*−*4.8CR3−0*UPN* unique patient number, *CR* complete remission, *ND* not done, "−" negative^a^The results of serial studies in 101 patients without GATA2 mutation at both diagnosis and relapse were not shown in this table^b^Interval between the two successive statuses

*GATA2* expression and biological functions associated with *GATA2* mutations {#Sec15}
-----------------------------------------------------------------------------

We analyzed the microarray dataset of 328 patients studied to assess the impact of *GATA2* mutations on gene expression and biological functions. By comparing the mRNA expression profiles between patients with and without *GATA2* mutations, we found *GATA2* expression levels were higher in those with *GATA2* mutations (*P* = 0.003). More specifically, both ZF1 and ZF2 mutations correlated with higher *GATA2* expression level compared to *GATA2* wild-type. *GATA2* mutations were associated with significant differential expression of 159 probes (*t*-test, *P* \< 0.05 and \>2-fold change). IPA analysis revealed different molecular networks between the *GATA2* ZF1 and ZF2-mutated group (Supplementary Figure [3](#MOESM1){ref-type="media"}). We also performed the GSEA analysis to identify biological functions associated with genes significantly enriched in *GATA2*-mutated AML, compared with *GATA2*-wild AML. Three-hundred and thirteen patients with wild-type *GATA2*, 12 patients with *GATA2* ZF1 mutations, and three patients with *GATA2* ZF2 mutations were analyzed. We identified significant underrepresentation of genes hyper-methylated in AML (*P* = 0.006; normalized enrichment score (NES) = −1.49; Supplementary Figure [4A](#MOESM1){ref-type="media"}) and genes related to apoptosis (*P* = 0.042; NES = −1.33) in the ZF1-mutated patients compared to *GATA2* wild-type patients. ZF2-mutations were associated with the Gene Oncology term of myeloid leukocyte differentiation (*P* = 0.03; NES = −1.46) (Supplementary Figure [4B](#MOESM1){ref-type="media"}). Comparing with ZF2-mutated AML, we identified significant overrepresentation of genes related to myeloid leukocyte differentiation (*P* = 0.042; NES = 1.36) and underrepresentation of genes hyper-methylated in AML (*P* = 0.029; NES = −1.37) in the ZF1-mutated AML.

Discussion {#Sec16}
==========

To the best of our knowledge, this is the first study to explore differences in clinical and biological implications between the *GATA2* ZF1 and ZF2 mutations in AML patients. We found that mutations in different domains were associated with distinct clinical features, co-occurring mutations and outcomes (Supplementary Table [3](#MOESM1){ref-type="media"}).

The *GATA2* mutation landscape in adult *de novo* AML differs from that in blastic crisis of CML^[@CR3]^, familial MDS/AML^[@CR4]^, and pediatric AML^[@CR5]^. In adult AML, ZF1 mutations predominate, while ZF2 mutations are reported sporadically^[@CR10],[@CR36],[@CR37]^. In concordance with the findings, two-thirds of the 44 distinct *GATA2* mutations in our study were located in the ZF1 domain. We also reported two novel missense mutations in ZF2 domain (L359V and G366R) that had not been reported before in adult *de novo* AML patients, but ever identified in blastic crisis of CML.

AML with *CEBPA*^double-mut^ has been included as a definite entity in the 2016 WHO Classification of Myeloid Neoplasms^[@CR15]^. It is well established that *GATA2* mutations frequently co-occur with *CEBPA*^double-mut^ with an incidence of 18--41%^[@CR9],[@CR10],[@CR12]^ and the two proteins show direct protein--protein interaction^[@CR38]^. Further study revealed *GATA2* ZF1 mutants, but not the ZF2 L359V that is commonly seen at the progression of CML to blast crisis, had reduced capacity to enhance *CEBPA*-dependent activation of transcription^[@CR9]^. Based on this functional study and the frequent co-occurrence of *CEBPA*^double-mut^ and ZF1 mutations, but not ZF2 mutations, in AML patients, it is possible that *GATA2* ZF1 mutations and *CEBPA*^double-mut^ interact together to induce leukemogenesis. In addition, we found ZF1 mutations were associated with lower incidences of *NPM1* mutations and *FLT3*-ITD than wild-type *GATA2*, different from ZF2 mutations as ZF2-mutated patients had similar incidences of these two mutations to those in *GATA2*-wild patients. *GATA2* ZF1 and ZF2 mutations may induce AML through different oncogenic mechanisms and have distinct impact on clinical outcomes. Truly, in this study, we demonstrated that patients with *GATA2* ZF1 mutations had a significantly longer OS than ZF2-mutated patients in total cohort, as well as in patients with intermediate-risk cytogenetics and normal karyotype.

The prognostic impact of *GATA2* mutations in *CEBPA*^double-mut^ patients was conflicting^[@CR12],[@CR13],[@CR37],[@CR39]^. Greif et al. and Theis et al. found that G*ATA2* mutations did not impact clinical outcome in *CEBPA*^double-mut^ patients. On the contrary, *GATA2* mutations correlated with improved survival among *CEBPA*^double-mut^ patients in other reports^[@CR12],[@CR13]^. In a study of Theis et al., 31 (74%) of *GATA2* mutations were detected in ZF1 domain, and 11 (26%) in ZF2 domain. They did not show different clinical outcomes with respect to *GATA2* ZF1 and ZF2 mutations in a cohort with both *CEBPA*^double-mut^ and *CEBPA*^single-mut^ patients^[@CR39]^. We were the first to investigate the prognostic implication of *GATA2* ZF1 mutations in *CEBPA*^double-mut^ patients and showed its association with a better DFS and a trend of longer OS than wild-type *GATA2* among the *CEBPA*^double-mut^ subgroup.

The poor prognostic impact of *GATA2* ZF2 mutations was also witnessed in blast crisis CML patients as in *de novo* AML patients shown in this study^[@CR4]^. The reason that ZF1 and ZF2 mutations had different survival impacts on de novo AML patients might be partially explained by their difference in association with *CEBPA*^double-mut^, and by different oncogenic mechanisms. Further studies are warranted to explore the underlying mechanisms of the differences.

The study also recruited the largest number of *de novo* AML patients for sequential analyses of *GATA2* mutations by NGS during clinical follow-ups. The original mutations in all 19 *GATA2-*mutated patients were lost at remission status, confirming them to be truly somatic mutations. We showed *GATA2* mutation was not stable during disease evolution. One (no. 27) of the six patients with *GATA2* mutations at diagnosis lost the mutation at relapse. Among the 105 patients who had no *GATA2* mutations at diagnosis, four (nos. 44, 45, 46, 47) acquired novel *GATA2* mutations at relapse. The four mutations were all ZF1 mutations.

In conclusion, *GATA2* ZF1 mutations, but not ZF2 mutations, are closely associated with *CEBPA*^double-mut^, and inversely correlated with *NPM1* mutations and *FLT3*-ITD. The two *GATA2* ZF domain mutations have different impacts on OS in AML patients. *GATA2* ZF1 mutations also affect clinical outcome in *CEBPA*^double-mut^ patients. Incorporation of *GATA2* ZF1, not ZF2 mutations, allows further refinement of the WHO Classification in the specific entity of AML with *CEBPA*^double-mut^.
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